JP2014524482A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524482A5 JP2014524482A5 JP2014527356A JP2014527356A JP2014524482A5 JP 2014524482 A5 JP2014524482 A5 JP 2014524482A5 JP 2014527356 A JP2014527356 A JP 2014527356A JP 2014527356 A JP2014527356 A JP 2014527356A JP 2014524482 A5 JP2014524482 A5 JP 2014524482A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- haloalkyl
- halo
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 57
- 150000001875 compounds Chemical class 0.000 claims 46
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 32
- 125000001475 halogen functional group Chemical group 0.000 claims 31
- 150000003839 salts Chemical class 0.000 claims 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 20
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 19
- 125000003545 alkoxy group Chemical group 0.000 claims 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 14
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 7
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 6
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 5
- 102000003939 Membrane transport proteins Human genes 0.000 claims 3
- 108090000301 Membrane transport proteins Proteins 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 230000009061 membrane transport Effects 0.000 claims 3
- 210000002569 neuron Anatomy 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 102100028662 Sigma intracellular receptor 2 Human genes 0.000 claims 2
- 101710109012 Sigma intracellular receptor 2 Proteins 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 238000010171 animal model Methods 0.000 claims 2
- -1 chloro, methyl Chemical group 0.000 claims 2
- 230000006999 cognitive decline Effects 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000007470 synaptic degeneration Effects 0.000 claims 2
- 230000031836 visual learning Effects 0.000 claims 2
- 102100037651 AP-2 complex subunit sigma Human genes 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 101000806914 Homo sapiens AP-2 complex subunit sigma Proteins 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 238000012347 Morris Water Maze Methods 0.000 claims 1
- 229940123586 Sigma 2 receptor antagonist Drugs 0.000 claims 1
- 230000002730 additional effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000003750 conditioning effect Effects 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 230000000971 hippocampal effect Effects 0.000 claims 1
- 230000013016 learning Effects 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000015654 memory Effects 0.000 claims 1
- 230000008897 memory decline Effects 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 210000000225 synapse Anatomy 0.000 claims 1
- 230000003976 synaptic dysfunction Effects 0.000 claims 1
- 230000032258 transport Effects 0.000 claims 1
- 0 C[C@@](CC([C@]1C(C)C(C)C1)N(*)*)c1ccccc1 Chemical compound C[C@@](CC([C@]1C(C)C(C)C1)N(*)*)c1ccccc1 0.000 description 7
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161527584P | 2011-08-25 | 2011-08-25 | |
| US61/527,584 | 2011-08-25 | ||
| PCT/US2012/052572 WO2013029057A2 (en) | 2011-08-25 | 2012-08-27 | Compositions and methods for treating neurodegenerative disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017133600A Division JP2017206545A (ja) | 2011-08-25 | 2017-07-07 | 神経変性疾患を処置する組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014524482A JP2014524482A (ja) | 2014-09-22 |
| JP2014524482A5 true JP2014524482A5 (https=) | 2016-03-31 |
Family
ID=47747105
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014527356A Pending JP2014524482A (ja) | 2011-08-25 | 2012-08-27 | 神経変性疾患を処置する組成物及び方法 |
| JP2017133600A Pending JP2017206545A (ja) | 2011-08-25 | 2017-07-07 | 神経変性疾患を処置する組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017133600A Pending JP2017206545A (ja) | 2011-08-25 | 2017-07-07 | 神経変性疾患を処置する組成物及び方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20170197977A9 (https=) |
| EP (1) | EP2747759A4 (https=) |
| JP (2) | JP2014524482A (https=) |
| CN (1) | CN104053435A (https=) |
| AU (1) | AU2012298614A1 (https=) |
| BR (1) | BR112014004414A2 (https=) |
| CA (1) | CA2846604A1 (https=) |
| HK (1) | HK1202248A1 (https=) |
| IL (1) | IL231157A0 (https=) |
| RU (1) | RU2014111079A (https=) |
| WO (1) | WO2013029057A2 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201404913QA (en) | 2009-04-09 | 2014-11-27 | Cognition Therapeutics Inc | Inhibitors of cognitive decline |
| RU2012107457A (ru) | 2009-07-31 | 2013-09-10 | Когнишн Терапьютикс, Инк. | Ингибиторы ухудшения когнитивных способностей |
| WO2015009742A2 (en) | 2013-07-15 | 2015-01-22 | Board Of Regents, The University Of Texas System | Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression, and neuropathic pain |
| DK3099296T3 (en) * | 2014-01-31 | 2019-04-15 | Cognition Therapeutics Inc | ISO-INDOLINE DERIVATIVES, COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE |
| WO2017041037A1 (en) * | 2015-09-04 | 2017-03-09 | The Trustees Of Columbia University In The City Of New York | Disruption of the interaction between amyloid beta peptide and dietary lipids |
| EP3448519A4 (en) | 2016-04-29 | 2020-01-22 | Board Of Regents, The University Of Texas System | SIGMA RECEPTOR BINDING |
| CN108226319A (zh) * | 2016-12-22 | 2018-06-29 | 亚宝药业集团股份有限公司 | 一种检测卡巴拉汀贴剂中光学异构体的方法 |
| EP3634394B1 (en) * | 2017-05-15 | 2025-12-24 | Cognition Therapeutics, Inc. | Compositions for treating neurodegenerative diseases |
| WO2021055670A1 (en) | 2019-09-20 | 2021-03-25 | Avx Corporation | Somatic cell-based electrical biosensor |
| EP4308565A4 (en) * | 2021-03-19 | 2025-01-01 | Cognition Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
| CN114882940B (zh) * | 2022-03-28 | 2022-11-08 | 北京玻色量子科技有限公司 | 一种基于相干伊辛机的分子对接方法和装置 |
| WO2025181805A1 (en) * | 2024-02-27 | 2025-09-04 | Prilenia Neurotherapeutics Ltd. | Pridopidine and sigma 2 antagonist agent for treating huntington disease and symptoms thereof |
| WO2026030341A1 (en) | 2024-07-29 | 2026-02-05 | Cognition Therapeutics, Inc. | Zervimesine for treating neurodegenerative disease |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA732136B (en) * | 1972-04-12 | 1974-03-27 | Lilly Co Eli | Dopamine derivatives |
| DK171627B1 (da) * | 1983-01-31 | 1997-03-03 | Lilly Co Eli | Anvendelse af beta-phenethanolamin og farmaceutiskacceptable salte deraf samt dyrefoderpræblanding med indhold deraf |
| US4697024A (en) * | 1986-11-24 | 1987-09-29 | Merrell Dow Pharmaceuticals Inc. | Medroxalol intermediates |
| EP0507863A4 (en) * | 1989-12-28 | 1993-07-07 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| DE4000610A1 (de) * | 1990-01-11 | 1991-07-18 | Knoll Ag | Verfahren zur herstellung von optisch aktiven 3-amino-1-arylbutanen und 3-benzylamino-1-arylbutanen |
| JP2818958B2 (ja) * | 1990-02-23 | 1998-10-30 | 塩野義製薬株式会社 | ４―（４―アルコキシフェニル）―２―ブチルアミン誘導体およびその製造法 |
| JPH045266A (ja) * | 1990-04-24 | 1992-01-09 | Toyo Pharma- Kk | ドパミン誘導体の製造方法 |
| CO5011072A1 (es) * | 1997-12-05 | 2001-02-28 | Lilly Co Eli | Etanolaminas pirazinil substituidas como agfonistas de los receptores |
| DE10027151A1 (de) * | 2000-05-31 | 2001-12-06 | Bayer Ag | Herbizide Mittel auf Basis von substituierten Carbonsäureamiden |
| US20100029654A1 (en) * | 2006-03-23 | 2010-02-04 | Mount Sinai School Of Medicine | Cardiovascular compositions and use of the same for the treatment of alzheimer's disease |
| CN101121670A (zh) * | 2007-09-11 | 2008-02-13 | 上海紫源制药有限公司 | 一种3,4-二甲氧基-N-[3-(4-甲氧基苯基)-1-甲基-正丙基]-β-苯乙胺盐酸盐的制备方法 |
| WO2010088450A2 (en) * | 2009-01-30 | 2010-08-05 | Celladon Corporation | Methods for treating diseases associated with the modulation of serca |
| SG10201404913QA (en) * | 2009-04-09 | 2014-11-27 | Cognition Therapeutics Inc | Inhibitors of cognitive decline |
| RU2012107457A (ru) * | 2009-07-31 | 2013-09-10 | Когнишн Терапьютикс, Инк. | Ингибиторы ухудшения когнитивных способностей |
| US20130071330A1 (en) * | 2010-02-26 | 2013-03-21 | Susan Catalano | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
| WO2012027548A1 (en) * | 2010-08-25 | 2012-03-01 | The Feinstein Institute For Medical Research | Compounds and methods for prevention and treatment of alzheimer's and other diseases |
| US9499462B2 (en) * | 2011-02-02 | 2016-11-22 | Cognition Therapeutics, Inc. | Isolated compounds from turmeric oil and methods of use |
| CA2846611A1 (en) * | 2011-08-25 | 2013-02-28 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
-
2012
- 2012-08-27 RU RU2014111079/15A patent/RU2014111079A/ru not_active Application Discontinuation
- 2012-08-27 BR BR112014004414A patent/BR112014004414A2/pt not_active IP Right Cessation
- 2012-08-27 WO PCT/US2012/052572 patent/WO2013029057A2/en not_active Ceased
- 2012-08-27 AU AU2012298614A patent/AU2012298614A1/en not_active Abandoned
- 2012-08-27 US US14/241,019 patent/US20170197977A9/en not_active Abandoned
- 2012-08-27 EP EP12824979.4A patent/EP2747759A4/en not_active Withdrawn
- 2012-08-27 HK HK15102756.3A patent/HK1202248A1/xx unknown
- 2012-08-27 CN CN201280052595.4A patent/CN104053435A/zh active Pending
- 2012-08-27 CA CA2846604A patent/CA2846604A1/en not_active Abandoned
- 2012-08-27 JP JP2014527356A patent/JP2014524482A/ja active Pending
-
2014
- 2014-02-25 IL IL231157A patent/IL231157A0/en unknown
-
2017
- 2017-07-07 JP JP2017133600A patent/JP2017206545A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524482A5 (https=) | ||
| RU2014111079A (ru) | Композиции и способы для лечения нейродегенеративного заболевания | |
| ES2530780T3 (es) | Composiciones y métodos para el tratamiento de trastornos oculares | |
| NO20090910L (no) | Sulfonamid-derivater som adrenerge agonister og muskariniske antagonister | |
| DE50313528D1 (de) | Substituierte indole und deren verwendung als 5ht-wiederaufnahme inhibitoren und als 5ht liganden | |
| JP2013540755A5 (https=) | ||
| ECSP088499A (es) | Nuevos compuestos de 2-amino-imidazol-4-ona y su uso en la fabricación de un medicamento para uso en el tratamiento de alteración cognitiva, enfermedad de alzheimer, neurodegeneración y demencia | |
| RU2016134677A (ru) | Композиции изоиндолина и способы лечения нейродегенеративного заболевания | |
| UY30414A1 (es) | Metano sulfonatos, propano-1-sulfonatos y ciclopropan sulfonatos sustituidos con [2,3,4,8-tetrahidroimidazo-[1,5-al-pirimidin-8-il]-fenilo, composiciones farmacéuticas conteniéndolos y aplicaciones. | |
| CR9214A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| ATE463495T1 (de) | Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten | |
| NO20082481L (no) | Nye 2-aminoheterosykluser som er nyttige ved behandling av ABETA-relaterte patologier | |
| NO20072978L (no) | Nye betuinderivater, preparat derav og anvendelse derav | |
| EP2379064A4 (en) | LONG CIRCULATING NANOTEHICLES FOR THE DELAYED RELEASE OF THERAPEUTIC AGENTS | |
| PE20140381A1 (es) | Dispersiones solidas extruidas por fusion que contienen un agente inductor de apoptosis | |
| JP2016520618A5 (https=) | ||
| BRPI0612072A2 (pt) | inibidores da aspartil protease | |
| EA200701745A1 (ru) | Циклопропанкарбоксамидные производные | |
| RU2014111078A (ru) | Композиции и способы для лечения нейродегенеративного заболевания | |
| ATE495167T1 (de) | Piperidin-4-yl-pyridazin-3-yl-aminderivate als schnell dissoziierende antagonisten des dopamin-2-rezeptors | |
| AR076362A1 (es) | Arilsulfonamidas 2,5-disustituidas antagonistas de ccr3, composiciones farmaceuticas que las contienen y uso de las mismas para el tratamiento y/o prevencion de patologias autoinmunes e inflamatorias, entre otras. | |
| NO20080165L (no) | Alfa-(aryl-OR heteroaryl-metyl)-beta piperidinopropanamidforbindelser som ORL1-receptorantagonister | |
| CN114364676A (zh) | 新型三环芳香杂环化合物,及其制备方法、药物组合物和应用 | |
| EA201070916A1 (ru) | Двойные фармакофоры - pde4-мускариновые антагонисты | |
| AR053435A1 (es) | Derivados de 5-amminoindol, un metodo para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un madicamento para el tratamiento de enfermedades asociadas a la modulacion de receptores h3. |